Targeting cardiovascular events to improve patient outcomes after sepsis
Targeting cardiovascular events to improve patient outcomes after sepsis
批准号:
10219343
负责人:
Allan J. Walkey
金额:
$66.84万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-07-15 至 2023-04-30
关键词:
AddressAdrenergic beta-AntagonistsAffectAftercareAmericanAmerican Heart AssociationAngiotensin-Converting Enzyme InhibitorsAnticoagulantsAntiplatelet DrugsAtrial FibrillationBenefits and RisksBiological MarkersCardiacCardiovascular DiseasesCardiovascular systemCessation of lifeCharacteristicsClinicalClinical TrialsCollaborationsDataData SetDiabetes MellitusEffectivenessElectronic Health RecordEventFutureGuidelinesHealthHeart InjuriesHeart failureHemorrhageHospitalizationHospitalsHyperlipidemiaHypertensionIndividualInfectionInflammationInfrastructureInjury to KidneyKnowledgeLifeMethodsModelingModificationMorbidity - disease rateMyocardial InfarctionOutcomePatient-Focused OutcomesPatientsPatternPerformancePharmaceutical PreparationsPhysiologicalPreventivePreventive therapyRecording of previous eventsRiskRisk EstimateRisk FactorsRisk ReductionSepsisStrokeStructureSurvivorsTherapeuticThrombophiliaTimeTreatment EffectivenessUnited StatesWorkbasecardioprotectioncardiovascular risk factorcomorbidityeffectiveness evaluationfunctional declinehigh dimensionalityhigh riskhospital readmissionimprovedinhibitor/antagonistinnovationinsightmodifiable riskmortalitynovelpatient populationpersonalized approachrandomized trialresponserisk prediction model
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT / PROJECT SUMMARY
We propose the “Targeting cardiovascular events to improve patient outcomes after sepsis” study to identify
opportunities to improve long-term patient outcomes after sepsis through the discovery of novel, potentially
modifiable, risk factors for post-sepsis cardiovascular events. Sepsis is a life-threatening, dysregulated
response to infection and the most common illness leading to hospitalization in the United States, affecting ~1
million Americans yearly. Cardiovascular complications are among the most common reasons for morbidity, re-
hospitalization and death after sepsis. Approximately 1 in 3 sepsis survivors are hospitalized for cardiovascular
events in the year following sepsis. Cardiovascular complications after sepsis are common, but the risk factors
are undefined and likely differ from traditional cardiac risk factors. In addition, prescribing patterns of potentially
cardio-protective medications are unclear and effectiveness of traditional cardiovascular risk-modifying
treatments after sepsis are uncertain. We propose to use longitudinal, granular, electronic health record data
across multiple centers to address knowledge gaps involving predictors of cardiovascular complications,
practice patterns of cardiovascular risk modification, and effectiveness of therapies prescribed to reduce
cardiovascular risk in the especially vulnerable period after sepsis. We have assembled a team with expertise
in using longitudinal electronic health record data to study novel cardiovascular risk factors and sepsis with
state-of-the-art methods. Results from our study will provide new insights into the common intersection of
sepsis with cardiovascular events and will inform current therapeutic strategies, as well as the conduct of future
randomized trials investigating novel methods to reduce cardiovascular complications and improve patient
outcome after sepsis.
期刊论文(14)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Variation in Use of Repurposed Medications Among Patients With Coronavirus Disease 2019. From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group.
2019年冠状病毒病患者使用重新利用药物的使用变化。从重症监护医学协会发现病毒感染和呼吸道疾病通用研究:2019年冠状病毒疾病登记研究员组。
DOI:
10.1097/cce.0000000000000566
发表时间:
2021-11
期刊:
Critical care explorations
影响因子:
--
作者:
[Garcia MA, Johnson SW, Bosch NA, Sisson EK, Sheldrick CR, Kumar VK, Boman K, Bolesta S, Bansal V, Deo N, Domecq JP, Lal A, Christie AB, Banner-Goodspeed VM, Sanghavi D, Vadgaonkar G, Gajic O, Kashyap R, Walkey AJ]
通讯作者:
Walkey AJ
SARS-CoV-2 With Concurrent Respiratory Viral Infection as a Risk Factor for a Higher Level of Care in Hospitalized Pediatric Patients.
SARS-CoV-2 并发呼吸道病毒感染是住院儿科患者接受更高水平护理的危险因素。
DOI:
10.1097/pec.0000000000002814
发表时间:
2022
期刊:
Pediatric emergency care
影响因子:
1.4
作者:
[Dikranian,Lea, Barry,Suzanne, Ata,Ashar, Chiotos,Katie, Gist,Katja, Bhalala,Utpal, Danesh,Valerie, Heavner,Smitty, Gharpure,Varsha, Bjornstad,EricaC, Irby,Olivia, Heneghan,JuliaA, Montgomery,Vicki, Gupta,Neha, Miller,Aaron, Walkey,Allan, ]
通讯作者:
Should We Agree to Disagree on Who May Benefit From ICU Admission?
关于谁可以从 ICU 入院中受益,我们应该同意还是不同意?
DOI:
10.1097/ccm.0000000000003495
发表时间:
2019
期刊:
Critical care medicine
影响因子:
8.8
作者:
[Law,AnicaC, Walkey,AllanJ]
通讯作者:
Walkey,AllanJ
External Validation of a Risk Score for Daily Prediction of Atrial Fibrillation among Critically Ill Patients with Sepsis.
脓毒症危重患者心房颤动每日预测风险评分的外部验证。
DOI:
10.1513/annalsats.202107-787rl
发表时间:
2022
期刊:
Annals of the American Thoracic Society
影响因子:
8.3
作者:
[Rucci,JustinM, Bosch,NicholasA, Quinn,EmilyK, Chon,KiH, McManus,DavidD, Walkey,AllanJ]
通讯作者:
Walkey,AllanJ
Exploring the Pathways Revealed by International Sepsis Benchmarking.
探索国际脓毒症基准测试揭示的途径。
DOI:
10.1097/ccm.0000000000003485
发表时间:
2019
期刊:
Critical care medicine
影响因子:
8.8
作者:
[Walkey,AllanJ]
通讯作者:
Walkey,AllanJ
共 9 条
Informing best practices for evaluation and treatment of myocardial injury during sepsis
-
批准号:10973324
-
项目类别:
-
资助金额:$75.73万
-
财政年份:2023
-
负责人:Allan J. Walkey
-
依托单位:
Targeting cardiovascular events to improve patient outcomes after sepsis
-
批准号:9923730
-
项目类别:
-
资助金额:$71.06万
-
财政年份:2018
-
负责人:Allan J. Walkey
-
依托单位:
Automated detection and prediction of atrial fibrillation during sepsis
-
批准号:9283910
-
项目类别:
-
资助金额:$54.45万
-
财政年份:2017
-
负责人:Allan J. Walkey
-
依托单位:
Automated detection and prediction of atrial fibrillation during sepsis
-
批准号:9910440
-
项目类别:
-
资助金额:$53.56万
-
财政年份:2017
-
负责人:Allan J. Walkey
-
依托单位:
Atrial Fibrillation in Sepsis: Patient Outcomes and Provider Practice Patterns
-
批准号:9002852
-
项目类别:
-
资助金额:$16.96万
-
财政年份:2013
-
负责人:Allan J. Walkey
-
依托单位:
Atrial Fibrillation in Sepsis: Patient Outcomes and Provider Practice Patterns
-
批准号:8425628
-
项目类别:
-
资助金额:$13.39万
-
财政年份:2013
-
负责人:Allan J. Walkey
-
依托单位:
Atrial Fibrillation in Sepsis: Patient Outcomes and Provider Practice Patterns
-
批准号:8617298
-
项目类别:
-
资助金额:$13.43万
-
财政年份:2013
-
负责人:Allan J. Walkey
-
依托单位:
Atrial Fibrillation in Sepsis: Patient Outcomes and Provider Practice Patterns
-
批准号:8791133
-
项目类别:
-
资助金额:$13.43万
-
财政年份:2013
-
负责人:Allan J. Walkey
-
依托单位:
Atrial Fibrillation in Sepsis: Patient Outcomes and Provider Practice Patterns
-
批准号:9205255
-
项目类别:
-
资助金额:$16.96万
-
财政年份:2013
-
负责人:Allan J. Walkey
-
依托单位:
Adiponectin in Acute Lung Injury
-
批准号:8262503
-
项目类别:
-
资助金额:$12.28万
-
财政年份:2012
-
负责人:Allan J. Walkey
-
依托单位:
Adiponectin in Acute Lung Injury
-
批准号:8466369
-
项目类别:
-
资助金额:$11.69万
-
财政年份:2012
-
负责人:Allan J. Walkey
-
依托单位: